The abstract is read at the publisher; the summary is JClub's.
Evidence of clinically relevant impact from artificial intelligence in drug discovery remains disappointingly limited despite a decade of growing interest and many developed, applied, and benchmarked methods.
- Why it matters: The field has not yet delivered safer, more efficacious medicines to patients faster, and the gap between technical progress and clinical translation remains unclear.
- What they did: This Perspective reviews progress and points to likely barriers, including limited clinical translation focus during model development, challenges with conditional life science data, and underspecified models for real-world use cases.
- The result: It recommends shifting benchmarking from model validation toward measuring improvements in decision making, alongside better problem definitions and operationalization for scaled, accessible user systems.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.